Alemtuzumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), NICE (England) and NYE METODER (Norway), among others, recommended or restricted alemtuzumab, while PBAC (Australia) did not recommend it.
The file has been open for more than a decade: 12.6 years separate the first record, 8 Sep 2008 at SMC (Scotland), from the most recent, 29 Apr 2021 at CONITEC (Brazil).
CONITEC (Brazil) changed its position: not recommended on 11 Oct 2017, recommended by 29 Apr 2021, after a resubmission.
No assessment is on file from HAS (France), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for alemtuzumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
6 distinct indication wordings are recorded for alemtuzumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess alemtuzumab, on 8 Sep 2008; NYE METODER (Norway) did not open a file until 17 Nov 2019 — an unusually long tail of 11.2 years between the earliest and latest system to look at it.
3 of the 8 agencies here assessed alemtuzumab more than once, CONITEC (Brazil) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for alemtuzumab.
The full ledger for alemtuzumab reads 5 recommended, 3 not recommended, 1 restricted and 1 other, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 29 Apr 2021 | Tratamento de pacientes com esclerose múltipla remitente recorrente com características comparáveis aos critérios de tra… | incorporated into SUS | source |
| NYE METODER (Norway) | 17 Nov 2019 | Første- og andrelinjebehandling av multippel sklerose (MS) | introduced | source |
| AOTMIT (Poland) | 5 Oct 2018 | Lemtrada reimbursement recommendation | recommended conditionally | source |
| PBAC (Australia) | 2018 | Relapsing remitting multiple sclerosis(RRMS) | The PBAC did not recommend the request to increase the price per vial for alemtuzumab for … | source |
| SMC (Scotland) | 8 Sep 2008 | for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate | withdrawn | source |
7 further decisions for alemtuzumab, across 6 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- teriflunomide — divergent outcome (recommended vs restricted) on a shared indication
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
Coverage: 12 decisions for alemtuzumab from 8 agencies, 2008 to 2021. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.